Literature DB >> 29650641

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.

Nicolas Martinez-Calle1,2,3, Paula Rodriguez-Otero4,2,3, Sara Villar4, Luis Mejías5, Ignacio Melero3,6, Felipe Prosper4,2,3,7, Patricia Marinello8, Bruno Paiva2,3,9, Miguel Idoate5, Jesus San-Miguel4,2,3,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29650641      PMCID： PMC6029537          DOI： 10.3324/haematol.2017.185777

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.

Authors:  B Paiva; A Azpilikueta; N Puig; E M Ocio; R Sharma; B O Oyajobi; S Labiano; L San-Segundo; A Rodriguez; I Aires-Mejia; I Rodriguez; F Escalante; A G de Coca; A Barez; J F San Miguel; I Melero
Journal:  Leukemia       Date:  2015-03-17       Impact factor: 11.528

Review 2.  Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.

Authors:  Jeffrey S Weber; Michael Postow; Christopher D Lao; Dirk Schadendorf
Journal:  Oncologist       Date:  2016-07-08

3.  Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab.

Authors:  Tomonori Tadokoro; Eri Keshino; Akitaka Makiyama; Takakazu Sasaguri; Koichi Ohshima; Harutaka Katano; Masahiro Mohri
Journal:  Circ Heart Fail       Date:  2016-10       Impact factor: 8.790

4.  Influenza myocarditis and myositis: case presentation and review of the literature.

Authors:  Kanwal Kumar; Mina Guirgis; Shelley Zieroth; Evelyn Lo; Alan H Menkis; Rakesh C Arora; Darren H Freed
Journal:  Can J Cardiol       Date:  2011-06-08       Impact factor: 5.223

5.  Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade.

Authors:  William H D Hallett; Weiqing Jing; William R Drobyski; Bryon D Johnson
Journal:  Biol Blood Marrow Transplant       Date:  2011-04-12       Impact factor: 5.742

6.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

Authors:  Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

7.  Autoantibodies to cardiac troponin associate with higher initial concentrations and longer release of troponin I in acute coronary syndrome patients.

Authors:  Kim Pettersson; Susann Eriksson; Saara Wittfooth; Emilia Engström; Markku Nieminen; Juha Sinisalo
Journal:  Clin Chem       Date:  2009-03-05       Impact factor: 8.327

Review 8.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Authors:  J M Michot; C Bigenwald; S Champiat; M Collins; F Carbonnel; S Postel-Vinay; A Berdelou; A Varga; R Bahleda; A Hollebecque; C Massard; A Fuerea; V Ribrag; A Gazzah; J P Armand; N Amellal; E Angevin; N Noel; C Boutros; C Mateus; C Robert; J C Soria; A Marabelle; O Lambotte
Journal:  Eur J Cancer       Date:  2016-01-05       Impact factor: 9.162

9.  Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.

Authors:  Heinz Läubli; Cathrin Balmelli; Matthias Bossard; Otmar Pfister; Kathrin Glatz; Alfred Zippelius
Journal:  J Immunother Cancer       Date:  2015-04-21       Impact factor: 13.751

10.  Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.

Authors:  Mehmet Asim Bilen; Sumit K Subudhi; Jianjun Gao; Nizar M Tannir; Shi-Ming Tu; Padmanee Sharma
Journal:  J Immunother Cancer       Date:  2016-06-21       Impact factor: 13.751
View more
  16 in total

1.  Pharmacogenomics for immunotherapy and immune-related cardiotoxicity.

Authors:  Jessica A Castrillon; Charis Eng; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

2.  Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.

Authors:  Ranjan Pathak; Anjan Katel; Erminia Massarelli; Victoria M Villaflor; Virginia Sun; Ravi Salgia
Journal:  Oncologist       Date:  2021-08-25

Review 3.  Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.

Authors:  Daniel Ronen; Aseel Bsoul; Michal Lotem; Suzan Abedat; Merav Yarkoni; Offer Amir; Rabea Asleh
Journal:  Vaccines (Basel)       Date:  2022-03-31

Review 4.  Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.

Authors:  Tomas Jelinek; Bruno Paiva; Roman Hajek
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

Review 5.  Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.

Authors:  Yu-Wen Zhou; Ya-Juan Zhu; Man-Ni Wang; Yao Xie; Chao-Yue Chen; Tao Zhang; Fan Xia; Zhen-Yu Ding; Ji-Yan Liu
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

6.  Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment.

Authors:  Kyung Hwan Kim; Joon Young Hur; Jinhyun Cho; Bo Mi Ku; Jiae Koh; June Young Koh; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn; Eui-Cheol Shin
Journal:  Oncoimmunology       Date:  2020-02-02       Impact factor: 8.110

7.  A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors.

Authors:  Jessica Castrillon Lal; Sherry-Ann Brown; Patrick Collier; Feixiong Cheng
Journal:  Cardiooncology       Date:  2021-05-28

8.  Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.

Authors:  Cirino Botta; Rita Maria Agostino; Vincenzo Dattola; Vittoria Cianci; Natale Daniele Calandruccio; Giovanna Bianco; Antonino Mafodda; Roberto Maisano; Eleonora Iuliano; Giovanna Orizzonte; Domenico Mazzacuva; Antonia Consuelo Falzea; Rita Emilena Saladino; Rocco Giannicola; Giorgio Restifo; Umberto Aguglia; Michele Caraglia; Pierpaolo Correale
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

Review 9.  Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.

Authors:  Emma Matzen; Lars Erik Bartels; Brian Løgstrup; Stine Horskær; Christina Stilling; Frede Donskov
Journal:  Cardiooncology       Date:  2021-08-09

Review 10.  Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy.

Authors:  Kyung Hwan Kim; Chang Gon Kim; Eui-Cheol Shin
Journal:  Immune Netw       Date:  2020-02-10       Impact factor: 6.303
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.